SANSURE BIOTECH INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 18.13 CNY | -2.16% |
|
-2.47% | -7.26% |
| Jun. 12 | Sansure Biotech's Tuberculosis Diagnostic Kit Gets EU Certification | MT |
| Apr. 26 | Sansure Biotech Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 33.09 times its estimated earnings per share for the ongoing year.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -7.26% | 1.46B | C | ||
| -10.64% | 11.61B | B+ | ||
| -11.02% | 7.65B | B- | ||
| +30.85% | 5.62B | C | ||
| -16.28% | 3.85B | C | ||
| +8.39% | 2.62B | - | - | |
| -64.67% | 2.37B | D+ | ||
| -10.53% | 2.24B | B- | ||
| +24.87% | 2.16B | C | ||
| -12.06% | 1.76B | D+ |
Investor Rating
Trading Rating
-
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
-
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
-
4 months Revenue revision
-
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
-
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 688289 Stock
- Ratings Sansure Biotech Inc.
